title: Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy.
abstract: OBJECTIVE
  To compare the antiemetic effectiveness and safety of oral granisetron plus dexamethasone with those of oral ondansetron plus dexamethasone administered before emetogenic chemotherapy.
  
  
  METHODS
  Randomized, prospective, multicenter, open-label study.
  
  
  METHODS
  University-teaching hospital and veterans health care system.
  
  
  METHODS
  Sixty-one chemotherapy-naïve patients scheduled to receive emetogenic antineoplastic agents.
  
  
  METHODS
  A single-dose oral granisetron 1 mg and dexamethasone 12 mg or single-dose oral ondansetron 16 mg and dexamethasone 12 mg was administered before chemotherapy.
  
  
  RESULTS
  Twenty-four hours after administration patients were contacted to assess nausea, emesis, and adverse events. There were no statistical differences in frequency of nausea or emesis between groups. Seventy-six percent and 82% of patients receiving ondansetron and granisetron, respectively, experienced no emesis 24 hours after chemotherapy. Complete protection from nausea occurred in 58% and 46% of patients receiving the drugs, respectively. Adverse events were similar between groups.
  
  
  CONCLUSIONS
  Oral granisetron 1 mg and ondansetron 16 mg plus dexamethasone are safe and effective in preventing nausea and vomiting related to emetogenic chemotherapy.
authors.affiliation: Department of Pharmacy, Scott & White Memorial Hospital, Temple, TX 76508, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Herrington
authors.forename: P
authors.initials: P
authors.lastname: Kwan
authors.forename: R R
authors.initials: RR
authors.lastname: Young
authors.forename: E
authors.initials: E
authors.lastname: Lagow
authors.forename: L
authors.initials: L
authors.lastname: Lagrone
authors.forename: M W
authors.initials: MW
authors.lastname: Riggs
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004639:Emetics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D017829:Granisetron / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced* / Q000517:prevention & control*; D017294:Ondansetron / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D003907:Dexamethasone; D004639:Emetics; D017829:Granisetron; D017294:Ondansetron